• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Thursday, February 2, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

The Biologics News And Reports Portal

by Duong
April 10, 2022
in Cambridge
the-biologics-news-and-reports-portal
Share on FacebookShare on Twitter

WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent

Details
Category: Proteins and Peptides
Published on Sunday, 10 April 2022 09:38
Hits: 50

CAMBRIDGE, MA, USA I April 08, 2022 I Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, today announced it presented promising preclinical data on its IL-2 and IL-12 INDUKINE™ molecules, WTX-124 and WTX-330, respectively, in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans.

“Our conditionally activated, novel prodrug INDUKINE molecules continue to demonstrate targeted anti-tumor responses that reflect their design and engineering, remaining inactive in peripheral tissue, then unleashing an immune response within the tumor microenvironment,” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf. “IL-2 and IL-12 are proinflammatory cytokines with great potential to treat people with cancer, but systemic toxicities and poor pharmaceutical properties have limited their clinical application. These data suggest our approach may overcome these limitations and address the shortcomings associated with current cytokine treatments.”

Dr. Seidel-Dugan will discuss Werewolf’s innovative PREDATOR™ protein engineering platform, in a talk entitled, “Transforming Powerful Proinflammatory Mechanisms Into Novel Therapies for Cancer Patients,” during AACR session “New Developments in Immunotherapy: Targeting and Localizing Cytokine Activity,” on Tuesday, April 12 at 12:30 PM CDT, in the Great Hall AD, Convention Center.

Both data posters are now available online to AACR Annual Meeting attendees, and can be viewed in person between 1:30-5:00 PM CDT on Monday, April 11, during the AACR session PO.IM02.13, “Immune Response to Therapies 1”, Poster Section 37.

The WTX-124 data are summarized in a poster entitled, “WTX-124 is a Novel IL-2 Prodrug that is Conditionally Activated in Tumors and Drives Anti-Tumor Immunity by Activating Tumor Infiltrating CD8+ T Cells” (Abstract #2054). These preclinical data demonstrate WTX-124:

  • is tumor-selective and generates significant anti-tumor activity in a CD8+ T Cell-dependent manner;
  • has a better therapeutic window than recombinant human IL-2 (rhIL-2) or half-life extended rhIL-2;
  • significantly shifts the transcriptional profile of the tumor microenvironment towards activation of various immune cell populations in both the MC38 and B16F10 models; and
  • preferentially activates tumor infiltrating CD8+ and CD4+ T cells, with limited evidence of systemic T cell activation.

The WTX-330 data are summarized in a poster entitled, “WTX-330 is a Conditionally Activated IL-12 Prodrug that Fundamentally Reprograms Tumor Infiltrating CD8+ T Cells and Drives Tumor Regression” (Abstract #2055). These preclinical data demonstrate that a surrogate WTX-330:

  • generates potent anti-tumor immunity in multiple syngeneic tumor models in a cleavage-dependent manner;
  • displays a significant expansion of the therapeutic window compared to recombinant IL-12;
  • induces an anti-tumor immune memory response;
  • fundamentally shifts the transcriptional profile within the tumor and activates tumor infiltrating cytolytic effector cells in the MC38, B16-F10, and EMT6 tumor models

WTX-124 and WTX-330 INDUKINE molecules consist of wild-type IL-2 and IL-12 cytokines, respectively, tethered to an inactivation domain to prevent activation in peripheral tissue, a tumor protease-sensitive linker to allow for activation in the tumor microenvironment, and a half-life extension domain to improve tumor exposure.

Werewolf is developing WTX-124 as a potential monotherapy or in combination with checkpoint inhibitors in multiple tumor types. The Company has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, to evaluate WTX-124 as a monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with solid tumors.

Werewolf is developing WTX-330 as a single agent for the treatment of relapsed or refractory advanced or metastatic solid tumors, or lymphoma failing standard of care.

The Company expects to file an Investigational New Drug Application (IND) for WTX-124 in the second quarter of 2022, and for WTX-330 in the third quarter of 2022.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

SOURCE: Werewolf Therapeutics

Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT